Developing a safe, while more convenient long-acting basal insulin for diabetic patients is still an unmet medical need. Thus, we conducted a comprehensive pre-clinical study of the novel ultra-long acting insulin analogue LAPSInsulin115. Pharmacokinetic/pharmacodynamic studies comparing LAPSInsulin115 with other basal insulins were conducted in db/dbmice. Insulin signaling in the major target organs was analysed by Western blot after single subcutaneous injection in wildtype male Wistar rats.
